Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.

Revenue
+10.2%
EPS
+450.0%
Free cash flow
+35.6%
Total debt
−6.91%

Quarter to June 2026, against a year earlier

23.74 1.57 −6.20%
Market cap
$11.8B
P/E
0.0×
Fwd P/E
161×
Dividend yield
—
F-score
5/9
Altman Z
1.28
Beneish M
−2.68
Dividend safety
n/a

Elanco Animal Health Incorporated 10-K filed Feb 24, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 9:19 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 25, 2025: 16 added · 17 removed · 56 modified; 2 with only figures updated

  1. Removed · Overview

    Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve. Our diverse, durable product portfolio is sold in more than 90 countries and serves animals across many species, primarily: dogs and cats (collectively, pet health) and cattle, poultry, swine, sheep and, prior to the divestiture of our aqua business in July 2024, aqua (collectively, farm animal). With this ability to reach the world's animals, we are committed to fulfilling our customer promise: To be your advocate and continually earn your trust, improving the health of animals and creating value through innovative products, expertise and service. Through our customer promise and our commitment to excellence, we strive to advance the well-being of animals, people and the planet, enabling us to realize our vision of Food and Companionship Enriching Life.